The kinase inhibition profiles of CDKI-73 and flavopiridol were very similar (Figure 2E) but the notional therapeutic indices for the two agents were remarkably different with CDKI-73 showing significantly enhanced selectivity for CLL cells over normal B-lymphocytes and CD34+ bone marrow cells. The gene discussed is CD34; the disease is B-cell chronic lymphocytic leukemia.